Emiltatug Ledadotin (Emi-Le, XMT-1660)
Emi-Le Phase 1/2 (includes EMBLEM-1 pivotal cohort)
Servier (registry sponsor Day One Biopharmaceuticals) · Phase 1/2 · Recruiting · Enrollment 360
| Arm | Population | Dose | Estimand | Comparator | Efficacy |
|---|---|---|---|---|---|
| Emi-Le, ACC efficacy cohort | R/M ACC, evaluable (n = 45) | Phase 1 doses (not stated in source) | Single arm | n/r | objective response rate: 35.6%, ASCO 2026disease control rate: 82.2%, ASCO 2026median duration of response: 7.4 months, ASCO 2026 |
| Emi-Le, post hoc aggressive subtype | ACC with solid histology or high-grade transformation (n = 32, post hoc) | Phase 1 doses (not stated in source) | Single arm | n/r | objective response rate: 46.9%, ASCO 2026; post hocmedian progression-free survival: 7.8 months, ASCO 2026; post hocmedian duration of response: 6.4 months, ASCO 2026; post hoc |
| Emi-Le, ACC safety cohort | ACC safety population (n = 48) | Phase 1 doses (not stated in source) | Single arm | n/r | n/r |
| EMBLEM-1 pivotal Phase 2 cohort | aggressive ACC (solid histology or high-grade transformation); primary endpoint ORR | 80 mg/m2, cap 160 mg | Single arm | n/r | n/r |